STAT3 inhibition induces apoptosis in cancer cells independent of STAT1 or STAT2 by Shodeinde, Adetola et al.
Signal transducers and activators of transcription 
(STATs) were originally discovered as mediators of 
signal transduction. Persistent aberrant activation of 
STAT3 is part of the malignant phenotype of hormone
-refractory prostate cancer and pancreatic cancer; this 
is thought to be mediated by homodimers of phos-
phorylated STAT3, which translocate to the nucleus.  
One consequence of persistently-activated STAT3 in 
malignant cells is that they depend upon it for survival.   
STAT3 is observed to heterodimerize with STAT1 and 
STAT2; however the contributions of STAT3:STAT1  
and STAT3:STAT2 heterodimers to the survival of 
malignant cells have not been investigated in detail. 
 Previously we reported that single-stranded 
oligonucleotides containing consensus STAT3 binding 
sequences (13410 and 13411) were more effective for 
inducing apoptosis in prostate cancer cells than an-
tisense STAT3 oligonucleotides. Control oligonucleo-
tides (scrambled sequences) had no effect. STAT3-
inhibiting oligonucleotide 13410, but not scrambled-
sequence oligonucleotides, induced apoptosis in pan-
creatic cancer cells as well.  Here we report that 13410 
and derivative olignucleotides induced apoptosis in 
STAT1-null and STAT2-null fibrosarcoma cell lines 
U3A and U6A, as well as in the parental fibrosarcoma 
cell line 2fTGH. The cell lines expressed constitutively
-activated STAT3 and depended on its activity for sur-
vival.  Forty-eight hr after transfection of 13410 or 
related oligonucleotides, significant apoptosis was ob-
served in 2fTGH, U3A and U6A cells. Scrambled-
sequence oligonucleotides had no effect on survival.  
These data indicate that neither STAT1 nor STAT2 
play significant roles in the maintenance of these cells, 
and by extension that STAT3:STAT1 and 
STAT3:STAT2 heterodimers regulate a different set of 
genes from STAT3:STAT3 homodimers. 
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Introduction 
 
     Transcription factors are latent proteins that bind to 
the genome upon activation, either inducing or repress-
ing gene expression. After activation, transcription 
factors bind to specific enhancer sequences on the ge-
nome upstream or near the promoter region of the gene 
regulated by the transcription factor. Signal transduc-
ers and activators of transcription (STAT) are part of 
the signal transduction pathway of many growth fac-
tors and cytokines and are activated by phosphoryla-
tion of tyrosine and serine residues by upstream 
kinases (Ihle 1996). For example, signaling by IL-6 
generally induces phosphorylation of STAT3 (Ihle 
1996). In benign cells, the signaling by STAT3 is un-
der tight regulation, so that the signal is transient. 
However, aberrant signaling by STAT3 is found in 
many types of malignancies: multiple myeloma, head 
and neck cancer, breast cancer, prostate cancer etc. 
(Barton et al. 2001, 2004a, Buettner et al. 2002, Catlett
-Falcone et al. 1999, Epling-Burnette et al. 2001, 
Grandis et al. 1998, van Bokhoven et al. 2003). Trans-
formed cells often express constitutively-activated 
STAT3; thereby become dependent on it for survival. 
Disruption of activation, expression, or activity of 
STAT3 results in apoptosis when cells express persis-
tently-activated STAT3 (Barton et al. 2004a). STAT3 
binds to two known sequences, hSIE and GAS (Seidel 
et al. 1995, Zhong et al. 1994, 2005), through which 
its anti-apoptotic and oncogenic effects are directed 
(Bromberg et al. 1999, Darnell 2005). These sites con-
tain the canonical STAT3 binding motifs TTC(N)2-
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4GAA or TT(N)4-6AA (Bromberg et al. 1999, Darnell 
2005). 
 Previously, we created a novel strategy for 
inhibiting STAT3 binding to the genome by employing 
oligonucleotides containing sequences related to the 
hSIE binding site (Barton et al. 2004b). We reported 
that these inhibitors induced apoptosis in prostate and 
pancreatic cancer cell lines in vitro, and furthermore 
reduced mean tumor volumes of DU-145 cells in vivo 
(Barton et al. 2004b, Lewis et al. 2008). We postulated 
that the inhibitors are specific for STAT3 but still need 
formal proof. This is especially important, in light of 
the fact that a) STAT3 and STAT1 share approxi-
mately 72% sequence homology (Lui et al. 2007), b) 
STAT1 is frequently expressed by many tumors ex-
pressing STAT3 and c) STAT1 may play a patho-
physiological role in certain types of cancer  (Buettner 
et al. 2002, Ernst et al. 2008, Kovacic et al. 2006). 
 Although STAT3 generally effects gene ex-
pression through STAT3:STAT3 homodimers, active 
heterodimeric forms of STAT3 with STAT1 have been 
observed (Ichiba et al. 2002, Wegenka et al. 1993). 
Like STAT3, STAT1, and to a lesser extent, STAT2 
are implicated in tumorigenesis (Clifford et al. 2003, 
Ernst et al. 2008), however, STAT1 activity appears to 
have both pro- and anti-tumorigenic effects (Khodarev 
et al. 2004, 2007, Kovacic et al. 2006, Torrero et al. 
2006). Inhibition of STAT3 by decoys was observed to 
have no effect on STAT1 activation in squamous cell 
carcinoma cell lines (Lui et al. 2007). Under the right 
circumstances, both STAT1 and STAT2 regulate cyto-
kine-stimulated growth (Gimeno et al. 2005); however 
STAT1 may be a tumor suppressor in some cells (Lui 
et al. 2007). 
 Based on these observations, we decided to see 
what role, if any STAT1 or STAT2 play in maintain-
ing the survival of STAT3-dependent cells. We deter-
mined that the fibrosarcoma cell lines express constitu-
tively-activated STAT3, which had not been examined 
before. Using STAT1-null and STAT2-null fibrosar-
coma cell lines and transfecting them with STAT3-
inhibiting oligonucleotides, we observed the induction 
of apoptosis by STAT3 inhibitors in the absence of 
STAT1 or STAT2 signaling. Scrambled-sequence oli-
gonucleotides had no effect. We conclude that neither 
STAT1 nor STAT2 activity contribute to STAT3-
mediated survival of transformed cells. Moreover, the 
activity of our novel anti-STAT3 oligonucleotides did 
not depend on either STAT1 or STAT2 activation. 
 
Materials and Methods 
 
Oligonucleotides and siRNA 
Sequences of oligonucleotides used are as follows: 
S T A T 3  i n h i b i t o r s  1 3 4 1 0   5 ’ -
AGCTTCATTTCCCGTAAATCCCTA-3’ (14) and 
13410a   5’-TCCCGTAAATCCCTA-3’ (15); control 
o l i g o n u c l e o t i d e s  1 3 7 7 8  5 ’ -
TATGATCTCCTCCGTAACTCTCAA-3’ (14) and 
13778a  5’-TATGATCTCCTCCGT-3’ (15). 
 Oligonucleotides were synthesized using phos-
phorothiorate chemistry by the Molecular Resources 
Facility at University of Medicine and Dentistry, New 
Jersey Medical School (Newark, NJ). The ribose moie-
ties for 5 bp at both 5’ and 3’ ends were modified with 
2’-O-methoxyl groups to increase stability of the oli-
gonucleotides and to provide higher hybridization af-
finity (Goethe et al. 2001, Guvakova et al. 1995). For 
determinations of transfection efficiencies, a fluores-
cent oligonucleotide (13778a) was synthesized and 
included in every transfection experiment. Pooled 
siRNA oligonucleotides to silence STAT1, STAT2, 
and STAT3 were obtained from Santa Cruz Biotech-
nology; specifically the human STAT1 siRNA cata-
logue #sc-44123, human STAT2 siRNA catalogue #sc-
29492, and human STAT3 siRNA catalogue #sc-
29493 were used.  Transfections were done as directed 
by the manufacturer, using the transfection reagent 
supplied by Santa Cruz Biotechnology. A FITC-
labeled scrambled sequence siRNA oligonucleotide 
from Santa Cruz Biotechnology was included in each 
experiment to determine transfection efficiencies. 
 
Cells and Plasmids 
U3A (STAT1-null), U6A (STAT2-null), and 2fTGH 
(parental) fibrosarcoma cell lines were the kind gift of 
George Stark, The Cleveland Clinic (Li et al. 1996). 
They were grown in DMEM plus 10% serum 
(Hyclone).  BPH-1 cells were the gift of Simon Hey-
ward, Vanderbilt University School of Medicine, and 
were grown in RPMI-1640 plus 10% serum. The DU-
145 human prostate cancer cell line and the PANC-1 
human pancreatic cancer cell line were obtained from 
the American Type Culture Collection (Manassas, 
VA); they were grown in DMEM/ Ham’s F-12 mixture 
plus 10% serum. Mycoplasma assays were performed 
on cell lines by real-time PCR (Mycosensor qPCR As-
say Kit; Stratagene, La Jolla, CA); all cell lines were 
found to be negative. 
 The dominant-negative STAT3β (DN-STAT3) 
(Huang et al. 2007) plasmid was the gift of David 
Tweardy, Baylor College of Medicine. Cell viabilities 
were determined using fluorescein diacetate (Sigma 
Chemical Co., St. Louis, MO) and a Universal RIII 
fluorescence microscope (Zeiss, Jena, Germany). 
 
Creation of STAT3-null BPH-DN-STAT3 cells 
LipoFectamine 2000 transfection reagent (Invitrogen) 
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was used to transfect DN-STAT3 into BPH-1 cells as 
described previously (Barton et al. 2004b). Briefly, 
cells plated in six-well plates were grown to ~50% 
confluence. DN-STAT3  and LipoFectamine 2000 
were diluted in Opti-MEM I separately as directed by 
Invitrogen. The diluted LipoFectamine 2000 was al-
lowed to incubate for 5 min at room temperature be-
fore mixing it with an equal volume of diluted plasmid 
for each well; mock transfected wells received Li-
poFectamine 2000 in the absence of plasmid. The lipo-
some-plasmid mixture was incubated at room tempera-
ture for 20 min before adding it to each well. Cells 
were incubated with the mixture for 6 hrs at 37 oC; 1.5 
ml per well of cell culture medium containing 30% 
serum was then added. Selection with G418 began 48 
hr post-transfection after cells were sorted for EGFP 
fluorescence on a FACSVantage SE cell sorter and 
continued until no surviving cells were observed in the 
mock-transfected well. The resulting cell line was 
cloned by limit dilution, which resulted in 1 clone ex-
pressing EGFP (BPH-DN-STAT3). 
 
Determination of Activated STAT3 by Intracellular 
Flow Cytometry 
In brief, cells were fixed in Medium A (Invitrogen), 
then washed in PBS. To enhance intracellular staining, 
cells were resuspended in ice-cold methanol for 15 
minutes on ice. After washing in PBS, cells were re-
suspended in Medium B containing 2 mg/ml goat Ig 
(Invitrogen) for 30 minutes at room temperature, then 
incubated with phycoerythrin (PE)-labeled rabbit anti-
phospho-STAT3 (Santa Cruz) or STAT5 (Cell Signal-
ing) at 1 μg Ab/106 cells in 100 μl buffer for 1 hour on 
ice, followed by washing in PBS. For analysis, cells 
were brought to 0.5 ml in buffer. All flow cytometric 
analyses were performed on a Becton-Dickinson FAC-
Scan, using the CellQuest Pro software. 
 
STAT3 Inhibitors 
The STAT3 inhibitors 13410 and 13410a, and the 
scrambled sequence control oligonucleotides have 
been described elsewhere (Barton et al. 2004b, Lewis 
et al. 2008). They were transfected into cells using Li-
poFectamine 2000 as described above. The JAK in-
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Figure 1.  Phospho-STAT3 expression in 2fTGH, U3A and U6A cells. Expression of activated (phospho) STAT3 by fibrosar-
coma cell lines. Parental 2fTGH, STAT1-null U3A, and STAT2-null U6A cells were fixed, permeabilized, blocked appropri-
ately and then incubated with PE-anti-phospho-STAT3 (Y-705) Ab. Fluorescence was quantified by flow cytometry. Green = 
control Ab (anti-P-STAT5 Ab); red = anti-P-STAT3 Ab. 
  
hibitor AG490 was obtained from Calbiochem.  It was 
dissolved in DMSO and then diluted in culture me-
dium as needed. 
 
Apoptosis Determinations 
Annexin V and propidium iodide (PI) or 7-amino-
actonomycin D (7-AAD) staining (Abcam, Malvern 
PA; Sigma, St. Louis MO) were used to measure the 
induction of apoptosis. Harvested cells were washed 
twice in buffer and resuspended, before addition of the 
forementioned chemicals. Fluorescence was quantified 
using a FACScan flow cytometer (Becton Dickinson, 
San Jose, CA) on at least 10,000 events using the 
CellQuest Pro software (Becton Dickinson). 
 Statistical Analysis 
The graphing program Kaleidagraph 4.2 (Synergy 
Software, Reading, PA) and the statistical program 
InStat3 (GraphPad Software, San Diego, CA) were 
used for data analyses.  
 
Results 
 
2fTGH, U3A, and U6A cells express activated 
STAT3 
Fibrosarcomas are known to overexpress STAT3 
(Lehnhardt et al., 2005) but the question of whether 
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Figure 2. Effect of STAT3 inhibition on U3A and U6A survival. (A) AG490 treatment x 24 hr; apoptosis. Effect of AG490 
treatment on STAT1 or 2 and time they were harvested and stained with FITC-annexin V/PI and analyzed by flow cytometry. 
(B) Effect of 13410 and 13410a in STAT1- and STAT2-null cells. U3A and U6A cells were treated with STAT3 inhibitors 
13410 and 13410a and control oligonucleotides 13778 and 13778a for 48 hr.  Cells were harvested and stained with FITC-
annexin V/PI to assess apoptosis by flow cytometry. Apoptosis experiments were conducted three times.  Data from a represen-
tative experiment are given. 
(A) 
(B) 
 
they express persistently-activated STAT3 has not yet 
been examined. Therefore, cells were stained with anti
-phospho-STAT3 and analyzed by flow cytometry.  
The histograms in Figure 1 show that 2fTGH, U3A, 
and U6A cells express phospho-STAT3 in the absence 
of any treatment. Thus our data demonstrate constitu-
tive expression of phosphorylated STAT3 by 2fTGH, 
U3A, and U6A cells. 
 To determine the role of phospho-STAT3 in 
the survival of the fibrosarcoma cell lines, the cells 
were treated with the JAK2 inhibitor AG490. Apop-
tosis was then quantified as described (Barton et al. 
2004). Figure 2A shows that 30 to 100 µM treatment 
with AG490 for 24 hours resulted in nearly 100% 
apoptosis of U3A and U6A cells, indicating that cells 
remain sensitive to the STAT3-inhibiting effects of the 
JAK2 inhibitor AG490, even in the absence of STAT1 
or STAT2 expression. 
 
Inhibition of STAT3 activity induced apoptosis in 
U3A and U6A cells 
AG490 is a JAK2 inhibitor. Although its effects on 
U3A and U6A provide evidence that inhibition of 
STAT3 is deleterious to the survival of these cell lines, 
this is not proof on its own, as JAK2 also activates 
STAT5, which has been implicated in tumor cell sur-
vival (Harir et al. 2007, Meier et al. 2009, Rocnik et 
al. 2006). To address the issue of whether direct inhi-
bition of STAT3 results in apoptosis in the absence of 
expression of either STAT1 or STAT2, oligonucleo-
tide inhibitors of STAT3 activity (Barton et al. 2004b, 
Lewis et al. 2008) were transfected into 2fTGH, U3A, 
and U6A cells.  Figure 2B shows that STAT3 inhibi-
tors 13410 and 13410a, but not 13778 or 13778a, in-
duced significant apoptosis (60-80%), as measured by 
FITC-annexin V plus PI staining, in U3A and U6A 
cells. These results are further proof that STAT3 inhi-
bition induces apoptosis in cancer cells that is inde-
pendent of STAT1 or STAT2 expression or activity. 
 
Silencing STAT1 or STAT2 expression in STAT3-
dependent cancer cell lines did not affect viability 
In order to confirm that neither STAT1 nor STAT2 
contribute to the survival of malignant cells, siRNA 
was used to silence their expression in DU-145 and 
PANC-1 cells. The latter are STAT3-dependent cell 
lines ie. undergo apoptosis when STAT3 expression or 
activity is inhibited (Barton et al. 2004a, Lewis et al. 
2008). Figure 3 and Table 1 show that 24 to 48 hours 
after transfection with either STAT1 or STAT2 
siRNA, no significant apoptosis was observed in DU-
145 or PANC-1 cells. Transfection efficiencies for 
siRNA were high, averaging >90% (not shown). 
Transfection of a control siRNA sequence supplied by 
Santa Cruz had no effect, whereas transfection of 
STAT3 siRNA induced significant apoptosis (Table 1).    
 In order to show that neither STAT1 nor 
STAT2 synergized with STAT3 (thereby contributing 
to apoptosis), pairs of pooled siRNAs at 250 nM each 
(i.e., STAT1 plus STAT3 or STAT2 plus STAT3) 
were transfected into DU-145 and PANC-1 cells.  
Apoptosis was measured using FITC-annexin V/PI and 
flow cytometry 24 hours after transfection. The results 
in Table 2 show that neither STAT1 nor STAT2 
siRNA synergized with STAT3 siRNA to induce apop-
tosis; the amount of apoptosis seen with 250 nM 
STAT3 siRNA was nearly the same in the presence or 
absence of either STAT1 or STAT2 siRNA (Table 2).  
Repeated ANOVA revealed no significant differences 
in the amount of apoptosis observed whether cells 
were treated with STAT3 siRNA alone or STAT3 
siRNA in combination with STAT1, STAT2, or con-
trol siRNA (P value was 0.99 for DU-145 cells and 
0.43 for PANC-1 cells; Table 2).  We concluded from 
these experiments that inhibition of STAT3 to induce 
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Cell Line siRNA nM %Apoptotic 
DU-145 
None - 0 
STAT1 
250 0.04 
500 0.01 
STAT2 
250 0.02 
500 0.07 
STAT3 
250 50.62 
500 35 
Control 
250 0.02 
500 0.13 
PANC-1 
None - 0 
STAT1 
250 0 
500 0.02 
STAT2 
250 0.01 
500 0.03 
STAT3 
250 12.1 
500 46.8 
Control 
250 0.07 
500 0 
Table 1. Effect of siRNA-mediation inhibition of STATs 1, 
2, and 3 on cell survival. Pooled siRNAs were purchased 
from Santa Cruz Laboratories.  They were transfected into 
cells using Lipofectamine 2000 according to Invitrogen’s 
protocol.  Twenty-four hr after transfection, cells were har-
vested, washed, stained with FITC-annexin V/PI, and ana-
lyzed by flow cytometry. Data from a representative experi-
ment are given. 
apoptosis is independent of either STAT1 or STAT2, 
in DU-145 and PANC-1 cells. 
 
Absence of STAT3 expression by BPH-DN-STAT3 
cells and effect of 13410 and 13410a on them 
In order to ensure that the novel STAT3 inhibitors 
13410 and 13410a had no pathway for apoptosis in-
duction other than through STAT3 inhibition, we cre-
ated a STAT3-null cell line from BPH-1 cells. This 
was generated by forcing the expression of the pseu-
dogene STAT3β in BPH-1 cells by transfecting a plas-
mid (Huang et al. 2007) and then selecting transfected 
cells by fluorescence-activated cell sorting. The results 
in Table 3 demonstrate that BPH-1 and BPH-DN-
STAT3 cells showed no apoptosis when either 13410 
or 13410a were transfected. These data demonstrate 
that under conditions where STAT3 activity is sup-
pressed, oligonucleotides 13410 and 13410a exhibited 
no ancillary pro-apoptotic activity. 
 
Discussion 
 
Our data demonstrate that neither STAT1 nor STAT2 
contributed to the survival of STAT3-addicted tumor 
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Figure 3. Effect of STAT1 and STAT2 gene silencing with siRNA in STAT3-dependent cell lines.  DU-145 and PANC-1 cells 
were treated with 500 nM pooled siRNA for 72 hr, at which time cells were harvested and stained with FITC-annexin V/PI and 
analyzed by flow cytometry. More than 95% of the cells were observed to be viable following siRNA transfection.  Transfec-
tion efficiencies ranged from 95 to 98% (not shown). 
 
Cell Line siRNA nM (each siRNA) % Apoptotic ±SEM P 
DU-145 
None - 0 0 
0.97 
STAT3 250 52.8 5.4 
STAT1+STAT3 250 49.8 10 
STAT2+STAT3 250 52.2 9.4 
Control+STAT3 250 50.8 10.7 
PANC-1 
None - 0 0 
0.47 
STAT3 250 38.2 10.7 
STAT1+STAT3 250 40.2 9.9 
STAT2+STAT3 250 32.7 12 
Control+STAT3 250 37.2 9.5 
Table 2. Lack of synergy between STAT1 or STAT2 and STAT3 siRNAs. Pooled siRNAs were purchased from Santa Cruz 
Laboratories. They were co-transfected into cells using Lipofectamine 2000 according to Invitrogen’s protocol.  Twenty-four hr 
after transfection, cells were harvested, washed, stained with FITC-annexin V/PI, and analyzed by flow cytometry. % apoptotic 
data were normalized to 100% transfection efficiency.  P value was determined by repeated ANOVA. 
  
cells. Furthermore, our data show that the novel 
STAT3 inhibiting oligonucleotides 13410 and 13410a 
have sufficient STAT3 specificity insofar as the oli-
gonucleotides did not induce apoptosis in a STAT3-
null BPH cell line, BPH-DN-STAT3. Thus we con-
clude from our data that STAT3 acts independently of 
STAT1 or STAT2 in promoting the survival of cancer 
cells and that our novel STAT3 inhibitors 13410 and 
13410 are selective STAT3 inhibitors. 
 Under the right circumstances, STAT1 and 
STAT2 can regulate cytokine-stimulated growth, even 
in opposition to STAT3 effects (Gimeno et al. 2005). 
However, neither transcription factor is known to act 
as a proto-oncogene, a trait shared by STAT3 and 
STAT5. These previous observations did not rule out 
the possibility that STAT3 interacts with either STAT1 
or STAT2 to promote tumor cell survival. Transfection 
of siRNA to silence expression of either STAT1 or 
STAT2 had no effect on the survival of DU-145 pros-
tate cancer or PANC-1 pancreatic cells (Figure 3 and 
Table 1), yet transfection of STAT3 siRNA induced 
significant apoptosis in these cells lines (Tables 1 and 
2). Inhibiting STAT3 in U3A (STAT1-null) or U6A 
(STAT-2-null) cell lines had no effect on cell survival; 
however both U3A and U6A cell lines were sensitive 
to the effects of the JAK2 inhibitor AG490 (which in-
hibits activation of STAT3) and the effects of the 
STAT3 inhibitors 13410 and 13410a. No effect on 
U3A or U6A cell survival was seen when either con-
trol oligonucleotides 13778 or 13778a were trans-
fected. 
 STAT3 usually regulates gene expression 
through STAT3:STAT3 homodimers; however, active 
heterodimeric forms of STAT3 with STAT1 have been 
noted, which bind preferentially to the sequence TTC
(N)3GAA, a canonical STAT3 binding motif (Lewis et 
al. 2008, Wegenka et al. 1993). STAT3:STAT2 het-
erodimers have not been described, presumably due to 
the inability of the STAT2 SH2 domain to bind to the 
major phosphorylated tyrosine site on STAT3 
(Wiederkehr-Adam et al. 2003). Independent of inter-
actions with STAT3, STAT1 and STAT2 (in common 
with STAT3) recruit p300/CBP in the course of trans-
activation, albeit to different extents (Paulson et al. 
1999). Like STAT3, STAT1, and to a lesser extent, 
STAT2, are implicated in tumorigenesis (Clifford et al. 
2003, Ernst et al. 2008); however STAT1 activity ap-
pears to have both pro- and anti-tumorigenic effects 
depending upon STAT1 activation (transient or consti-
tutive) (Khodarev et al. 2004, Khodarev et al. 2007, 
Kovacic et al. 2006, Torrero et al. 2006). Inhibition of 
STAT3 by oligonucleotide decoys was observed to 
have no effect on STAT1 activation in squamous cell 
carcinoma cell lines (Lui et al. 2007). In addition, we 
could find no published data on the effect that STAT3 
inhibition has on STAT2 activation. Under the right 
circumstances, STAT1 and STAT2 can regulate cyto-
kine-stimulated growth, even in opposition to STAT3 
effects (Gimeno et al. 2005).   
 As expected, expression of STAT1 or STAT2 
may regulate tumor cell response to interferons. Stable 
expression of a dominant-negative form of STAT2 in 
squamous cell carcinoma cell lines blocked interferon-
α action as demonstrated by cell growth in its pres-
ence. On the other hand, expression of STAT1 or 
STAT2 in melanoma cell lines did not correlate with 
interferon-α as adjuvant therapy (Lesinski et al. 2005). 
More recently, investigators observed that a mutation 
in the SH2 domain of STAT2 prolonged tyrosine phos-
phorylation of STAT1, thereby promoting interferon-
induced apoptosis (Lesinski et al. 2005). These data 
may be an indication of interaction between STAT1 
and STAT2; more work is needed to determine if this 
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Table 3. Effect of anti-STAT3 oligonucleotides on STAT3-
null cells. BPH-1 cells and BPH-DN-STAT3 cells were 
transfected with olignucleotides as described in Materials and 
Methods.  Forty-eight hrs later, cells were harvested and 
stained with annexin-V and PI to assess apoptosis by flow 
cytometry.  The means plus standard deviations of three ex-
periments are given. 
Cell 
Line 
OLG nM 
%  
Apoptotic 
± SD 
BPH-1 
None 0 0.17 0.27 
13410 
100 0 0 
300 0 0 
1000 0.04 0.07 
13410a 
100 0 0 
300 0.02 0.01 
1000 0.07 0.1 
13778 
100 0 0 
300 0.3 0.29 
1000 0.08 0.14 
13778a 
100 0.04 0.03 
300 0.06 0.05 
1000 0.37 0.66 
BPH-
DN-
STAT3 
None 0 1.94 1.77 
13410 
100 0.4 0.37 
300 0.52 0.46 
1000 0.87 0.12 
13410a 
100 0.63 0.55 
300 1.02 0.89 
1000 2.25 1.05 
13778 
100 1.29 1.13 
300 0.53 0.46 
1000 1.48 0.16 
13778a 
100 0.47 0.41 
300 0.56 0.49 
1000 2.60 2.55 
is true in other cancer cell lines. In addition, very re-
cent data demonstrated that the STAT1 gene is a target 
of microRNA-145 in colon cancer cells, indicating that 
inhibiting STAT1 may be therapeutic for cancer treat-
ment (Gregersen et al. 2010). Clearly, more work de-
lineating the roles of STAT1, STAT2, and STAT3 in 
cancer is in order for understanding oncogenesis and 
for developing better treatment options. 
 
Acknowledgements 
 
The authors acknowledge the Molecular Resources 
Facility, New Jersey Medical School, for synthesizing 
the modified oligonucleotides used. This work was 
supported by NIH grant CA 121782, an award from 
the Elsa U. Pardee Foundation, and a Research & De-
velopment Merit Award from the Department of Vet-
erans Affairs (BEB).   
 
Competing interests 
 
The authors declare no conflicts of interest.  
 
Author Contributions 
 
A.L.S. contributed significantly to this manuscript. 
K.G. and H.D.L. contributed equally to this manu-
script. S.R. contributed to this manuscript. B.E.B. is 
the corresponding author. 
 
References 
 
Barton BE, Karras JG, Murphy TF, Barton AB & 
Huang HF 2004a STAT3 Activation in Prostate Can-
cer: Direct STAT3 Inhibition Induces Apoptosis in 
Prostate Cancer Lines. Mol Cancer Ther 3 11-20. 
Barton BE, Murphy TF, Adem P, Watson RA, Irwin 
RJ & Huang HS 2001 IL-6 signaling by STAT3 par-
ticipates in the change from hyperplasia to neoplasia in 
NRP-152 and NRP-154 rat prostatic epithelial cells. 
BMC Cancer 1 19.  
Barton BE, Murphy TF, Shu P, Huang HF, Meyen-
hofen M & Barton AB 2004b Novel Single-Stranded 
Oligonucleotides that Inhibit STAT3 Induce Apoptosis 
In Vitro and In Vivo in Prostate Cancer Cell Lines. 
Mol Cancer Ther 3 1183-1191.  
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao 
Y, Pestell RG, Albanese C & Darnell JE 1999 Stat3 as 
an oncogene. Cell 98 295-303. 
Buettner R, Mora LB & Jove R 2002 Activated STAT 
signaling in human tumors provides novel molecular 
targets for therapeutic intervention. Clin Cancer Res 8 
945-954.  
Catlett-Falcone R, Landowski TH, Oshiro MM, Turk-
son J, Levitzki A, Savino R, Ciliberto G, Moscinski L, 
Fernández-Luna JL, Nuñez G, Dalton WS & Jove R 
1999 Constitutive activation of Stat3 signaling confers 
resistance to apoptosis in human U266 myeloma cells. 
Immunity 10 105-115. 
Clifford JL, Yang X, Walch E, Wang M & Lippman 
SM 2003 Dominant negative signal transducer and 
activator of transcription 2 (STAT2) protein: stable 
expression blocks interferon alpha action in skin 
squamous cell carcinoma cells. Molecular Cancer 
Therapeutics 2 453-459. 
Darnell Jr JE 2005 Validating Stat3 in cancer therapy. 
Nat Med 11 595-596.  
Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turk-
son J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-
Yen HF, Karras J, Jove R & Loughran TP Jr 2001 In-
hibition of STAT3 signaling leads to apoptosis of leu-
kemic large granular lymphocytes and decreased Mcl-
1 expression. J Clin Invest 107 351-362. 
Ernst M, Najdovska M, Grail D, Lundgren-May T, 
Buchert M, Tye H, Matthews VB, Armes J, Bhathal 
PS, Hughes NR, Marcusson EG, Karras JG, Na S, 
Sedgwick JD, Hertzog PJ & Jenkins BJ 2008 STAT3 
and STAT1 mediate IL-11-dependent and inflamma-
tion-associated gastric tumorigenesis in gp130 receptor 
mutant mice. J Clin Invest 118 1727-1738. 
Gimeno R, Lee CK, Schindler C & Levy DE 2005 
Stat1 and Stat2 but not Stat3 arbitrate contradictory 
growth signals elicited by alpha/beta interferon in T 
lymphocytes. Mol Cell Biol 25 5456-5465. 
Goethe JW, Bittova M, Vogel JU, Kotchekov R, Doerr 
HW & Cinati Jr. J 2001 Antisense oligonucleotide 
ISIS 2922 targets IE-expression and prevents HCMV-
IE-induced suppression of TSP-1 and TSP-2 expres-
sion. Nucleosides Nucleotides Nucleic Acids 20 1425-
1428.  
Grandis JR, Drenning SD, Chakraborty A, Zhou M-Y, 
Zang Q, Pitt AS & Tweardy DJ 1998 Requirement of 
Stat3 but not Stat1 activation for epidermal growth 
factor receptor-mediated cell growth in vitro. J Clin 
Invest 102 1385-1392. 
Gregersen LH, Jacobsen AB, Frankel LB, Wen J, 
Krogh A & Lund AH 2010 MicroRNA-145 targets 
YES and STAT1 in colon cancer cells. PLoS One 5 
e8836. 
Guvakova MA, Yakubov LA, Vlodavesky I, Tonkin-
son JL & Stein CA 1995 Phosphothiorate oligode-
oxynucleotides bind to basic fibroblast growth factor, 
inhibit its binding to cell surface receptors, and remove 
it from low affinity binding sites on extracellular ma-
trix. J Biol Chem 270 2620-2627. 
Harir N, Pecquet C, Kerenyi M, Sonneck K, Kovacic 
B, Nyga R, Brevet M, Dhennin I, Gouilleux-Gruart V, 
Beug H, Valent P, Lassoued K, Moriggl R & Gouil-
25   Journal of Molecular Biochemistry, 2013 
leux F 2007 Constitutive activation of Stat5 promotes 
its cytoplasmic localization and association with PI3-
kinase in myeloid leukemias. Blood 109 1678-1686. 
Huang Y, Qiu, J, Dong S, Redell MS, Poli V, Mancini 
MA & Tweardy DJ 2007 Stat3 isoforms, alpha and 
beta, demonstrate distinct intracellular dynamics with 
prolonged nuclear retention of Stat3beta mapping to its 
unique C-terminal end. J Biol Chem 282 34958-34967. 
Ichiba M, Miyazaki Y, Kitamura S, Kiyohara T, Shi-
nomura Y & Matsuzawa Y 2002 Epidermal growth 
factor inhibits the growth of TE8 esophageal cancer 
cells through the activation of STAT1. J Gastroenterol 
37 497-505. 
Ihle JN 1996 STATs and MAPKs: obligate or oppor-
tunistic partners in signaling. BioEssays 18 95-98.  
Khodarev NN, Beckett M, Lebay E, Darga T, Roizman 
B & Weichselbaum RR 2004 STAT1 is overexpressed 
in tumors selected for radioresistance and confers pro-
tection from radiation in transduced sensitive cells. 
Proc Natl Acad Sci USA 101 1714-1719. 
Khodarev NN, Minn AJ, Efimova EV, Darga TE, La-
bay E, Beckett M, Mauceri HJ, Roizman B & Weich-
selbaum RR 2007 Signal Transducer and Activator of 
Transcription 1 Regulates Both Cytotoxic and Prosur-
vival Functions in Tumor Cells. Cancer Res 67 9214-
9220. 
Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, 
Kreibich R, Levy DE, Beug H, Freissmuth M & Sexl 
V 2006 STAT1 acts as a tumor promoter for leukemia 
development. Cancer Cell 10 77-87.  
Lehnhardt M, Klein-Hitpass L, Kuhnen C, Homann 
HH, Daigeler A, Steinau HU, Roehrs S, Schnoor L, 
Steinstraesser L & Mueller O 2005 Response rate of 
fibrosarcoma cells to cytotoxic drugs on the expression 
level correlates to the therapeutic response rate of fi-
brosarcomas and is mediated by regulation of apop-
totic pathways. BMC Cancer 5 74.  
Lesinski GB, Valentino D, Hade EM, Jones S, Magro 
C, Chaudhury AR, Walker MJ & Carson WE 3rd 2005 
Expression of STAT1 and STAT2 in malignant mela-
noma does not correlate with response to interferon-
alpha adjuvant therapy. Cancer Immunol Immunother 
54 815-825. 
Lewis HD, Winter A, Murphy TF, Tripathi S, Pandey 
VN & Barton BE 2008 STAT3 inhibition in prostate 
and pancreatic cancer lines by STAT3 binding se-
quence oligonucleotides: differential activity between 
5' and 3' ends. Mol Cancer Ther 7 1543-1550. 
Li X, Leung S, Qureshi S, Darnell JE Jr & Stark GR 
1996 Formation of STAT1-STAT2 heterodimers and 
their role in the activation of IRF-1 gene transcription 
by interferon-alpha. J Biol Chem 271 5790-5794. 
Lui VW, Boehm AL, Koppikar P, Leeman RJ, John-
son D, Ogagan M, Childs E, Freilino M & Grandis JR 
2007 Antiproliferative Mechanisms of a Transcription 
Factor Decoy Targeting Signal Transducer and Activa-
tor of Transcription (STAT) 3: The Role of STAT1. 
Mol Pharmacol 71 1435-1443. 
Meier C, Hoeller S, Bourgau C, Hirschmann P, 
Schwaller J, Went P, Pileri SA, Reiter A, Dirnhofer S 
& Tzankov A 2009 Recurrent numerical aberrations of 
JAK2 and deregulation of the JAK2-STAT cascade in 
lymphomas. Mod Pathol 22 476-487. 
Paulson M, Pisharody S, Pan L, Guadagno S, Mui AL 
& Levy DE 1999 Stat protein transactivation domains 
recruit p300/CBP through widely divergent sequences. 
J Biol Chem 274 25343-25349. 
Rocnik JL, Okabe R, Yu JC, Lee BH, Giese N, Schen-
kein DP & Gilliland DG 2006 Roles of tyrosine 589 
and 591 in STAT5 activation and transformation medi-
ated by FLT3-ITD. Blood 108 1339-1345. 
Seidel H, Milocco L, Lamb P, Darnell JJ, Stein R & 
Rosen J 1995 Spacing of palindromic half sites as a 
determinant of selective STAT (signal transducers and 
activators of transcription) DNA binding and transcrip-
tional activity. Proc Natl Acad Sci USA 92 3041-3045. 
Torrero MN, Xia X, Henk W, Yu S & Li S 2006 Stat1 
deficiency in the host enhances interleukin-12-
mediated tumor regression. Cancer Res 66 4461-4467.  
van Bokhoven A, Varella-Garcia M, Korch C, Johan-
nes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ 
& Lucia MS 2003 Molecular characterization of hu-
man prostate carcinoma cell lines. Prostate 57 205-
225.  
Wegenka UM, Buschmann J, Lutticken C, Heinrich 
PC & Horn F 1993 Acute-phase response factor, a nu-
clear factor binding to acute-phase response elements, 
is rapidly activated by interleukin-6 at the posttransla-
tional level. Mol Cell Biol 13 276-288.  
Wiederkehr-Adam M, Ernst P, Müller K, Bieck E, 
Gombert FO, Ottl J, Graff P, Grossmüller F & Heim 
MH 2003 Characterization of Phosphopeptide Motifs 
Specific for the Src Homology 2 Domains of Signal 
Transducer and Activator of Transcription 1 (STAT1) 
and STAT3. J Biol Chem 278 16117-16128. 
Zhong M, Henriksen MA, Takeuchi K, Schaefer O, 
Liu B, ten Hoeve J, Ren Z, Mao X, Chen X, Shuai K 
& Darnell JE Jr 2005 Implications of an antiparallel 
dimeric structure of nonphosphorylated STAT1 for the 
activation-inactivation cycle. Proc Natl Acad Sci U S A 
102 3966-3971. 
Zhong Z, Wen Z & Darnell JE Jr 1994 Stat3: a STAT 
family member activated by tyrosine phosphorylation 
in response to epidermal growth factor and interleukin-
6. Science, 264 95-98. 
Journal of Molecular Biochemistry, 2013   26 
